The last participant has completed all predefined assessments in the Phase 3 COGNITE clinical trial, which is assessing the safety and effectiveness of AZTherapies’ treatment candidate ALZT-OP1 for people with early Alzheimer’s disease. The trial’s top-line results are expected in the first months of 2021. The biopharmaceutical…
A recent report found deep social inequalities in U.S. counties with the highest Alzheimer’s rates among Blacks and Latinos. Inequalities related to education, income, food insecurity, and the physical environment are collectively known as social determinants of health and are inextricably tied to location, according to the report from…
A Phase 1 trial is enrolling patients with mild to severe dementia from Alzheimer’s disease to test IGC-AD1, an investigational cannabis-based treatment being developed India Globalization Capital (IGC) Pharma, a subsidiary of IGC, according to a recent press release. In the placebo-controlled study, 12 participants will…
AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its therapy candidates for Alzheimer’s disease, the company announced. The trial follows the release of the first positive clinical results, in which ACD856 showed…
Most of the mild to moderate Alzheimer’s patients enrolled in the atuzaginstat (COR388) Phase 2/3 trial show evidence of systemic infection due to Porphyromonas gingivalis, a bacteria linked to periodontal disease whose toxic enzymes are thought to contribute to Alzheimer’s and are targets for this candidate therapy. A “high proportion” also test…
The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy AMX0035 in people with Alzheimer’s disease. Top-line results from the trial are expected in the first half of…
The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with Alzheimer’s disease. The randomized, double-blinded, placebo-controlled trial is expected to enroll more than 500 people with mild…
An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy in treating Alzheimer’s disease.  In votes, eight of the committee’s 11 members found Phase 3 EMERGE data did not…
The European Medicines Agency (EMA) has agreed to review Biogen and Eisai’s application requesting the approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease. The companies’ approval request — in the form of a marketing authorization application (MAA) — will be analyzed by the EMA following…
Efforts are underway this month to focus attention on Alzheimer’s, a disease that, along with other forms of dementia, affects some 44 million people globally and is swiftly growing in prevalence. During November in the U.S., Alzheimer’s Awareness Month observances include fundraisers, disseminating tips for healthy aging, downloadable Alzheimer’s information,…
Get regular updates to your inbox.